Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 23;73(3):407-441.
doi: 10.1136/gutjnl-2023-331164.

RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates

Collaborators, Affiliations
Review

RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates

Massimo Rugge et al. Gut. .

Abstract

At the end of the last century, a far-sighted 'working party' held in Sydney, Australia addressed the clinicopathological issues related to gastric inflammatory diseases. A few years later, an international conference held in Houston, Texas, USA critically updated the seminal Sydney classification. In line with these initiatives, Kyoto Global Consensus Report, flanked by the Maastricht-Florence conferences, added new clinical evidence to the gastritis clinicopathological puzzle.The most relevant topics related to the gastric inflammatory diseases have been addressed by the Real-world Gastritis Initiative (RE.GA.IN.), from disease definitions to the clinical diagnosis and prognosis. This paper reports the conclusions of the RE.GA.IN. consensus process, which culminated in Venice in November 2022 after more than 8 months of intense global scientific deliberations. A forum of gastritis scholars from five continents participated in the multidisciplinary RE.GA.IN. consensus. After lively debates on the most controversial aspects of the gastritis spectrum, the RE.GA.IN. Faculty amalgamated complementary knowledge to distil patient-centred, evidence-based statements to assist health professionals in their real-world clinical practice. The sections of this report focus on: the epidemiology of gastritis; Helicobacter pylori as dominant aetiology of environmental gastritis and as the most important determinant of the gastric oncogenetic field; the evolving knowledge on gastric autoimmunity; the clinicopathological relevance of gastric microbiota; the new diagnostic horizons of endoscopy; and the clinical priority of histologically reporting gastritis in terms of staging. The ultimate goal of RE.GA.IN. was and remains the promotion of further improvement in the clinical management of patients with gastritis.

Keywords: AUTOIMMUNITY; GASTRIC CARCINOMA; GASTRIC PRE-CANCER; GASTROINTESTINAL PATHOLOGY; HELICOBACTER PYLORI - GASTRITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DSB has served as speaker for Abbott, AstraZeneca, Alfasigma, Biocodex, Pfizer, Reckitt Benckiser, Takeda, KRKA, PRO.MED.CS Praha and Dr Reddy’s Laboratories. LGC has served as speaker for Takeda and EMS. FDM has served as consultant for Biohit Healthcare. MD-R has served as consultant for Roche and Medtronic. DD has served as consultant for Reckits, Dr Reddy’s, Zentiva, AbbVie, Terapia and Takeda. EME-O is Editor of Gut. EJK is member of the Editorial Board of Gut. MLe has served as research consultant for Eiken Chemical. MLi has served as speaker for Abbott, AstraZeneca, Alfasigma, Biocodex, KRKA and PRO.MED.CS Praha. TM-B received research grants from: AstraZeneca, BMS, Biohit and Fujirebio; and has been involved in congresses and educational supported by AAA, AstraZeneca, MSD, BMS, Viatris and Pierre Fabre. FM has served as consultant for Phathom and Biocodex. ES has served as speaker for AbbVie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, Mayoly Biohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots and Unifarco; has served as consultant for AbbVie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr Falk, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestlè, Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas, Takeda and Unifarco; and has received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco and Zeta Farmaceutici. NS has served as speaker for Astellas and consultant for Bristol-Myers Squibb. KS has served as consultant for Fuji Film Co. NU has served as speaker for lectures for: Olympus Co, Fuji Film Co, Boston Scientific Japan, Daiichi-Sankyo Co, Takeda Pharmaceutical Co, EA Pharma Co, Otsuka Pharmaceutical Co, AstraZeneca Co, Miyarisan Pharmaceutical Co and AI Medical Service Co.

Publication types

LinkOut - more resources